Filterlex Medical News
6 articles
growth-positive
Filterlex Medical Announces Positive Results from A First-In-Human Study for the CAPTIS® Full-Body Embolic Protection Device
Filterlex Medical Ltd., a cardiovascular medical device startup, announced successful results from a first-in-human study of their CAPTIS device. The device, a full-body embolic protection device, demonstrated safety, feasibility, and performance during a Transcatheter Aortic Valve Replacement (TAVR) procedure. The study involved 20 patients with no complications or device-related issues. The CAPTIS device was successfully deployed and retrieved in all patients, and no patients experienced cerebrovascular events. The company plans to continue building clinical evidence for the devices use in TAVR procedures.
Customers
growth-positive
Filterlex Medical Raises €7M to Revolutionize Embolic Protection - Grit Daily News
Filterlex Medical, a cardiovascular medical device startup, has been selected to receive €7 Million equity investment from the European Innovation Council Accelerator (EIC). The investment will go towards clinical program expansion, regulatory approvals, and commercialization of the CAPTIS full-body embolic protection system. Filterlexs technology was chosen as one of the winning companies out of over 1000 applicants to receive EIC funding. This investment follows Filterlexs recent series A1 investment round of US $6 Million. The company is also a past recipient of a €2.1 Million EU Horizon 2019 grant. Filterlex is currently enrolling patients in its CAPTIS first-in-human study in Israel.
Investment
growth-positive
Filterlex Medical Closes a $6Million Series A1 Investment to Accelerate the CAPTIS® Cardiovascular Clinical Program
Filterlex Medical, a cardiovascular medical device startup, has completed a US $6 Million series A1 investment round from leading private healthcare investors. The funding will accelerate the implementation of the companys CAPTIS® clinical program, which focuses on a next-generation, full-body embolic protection device to reduce the risk of stroke and other complications during left-heart procedures. The CAPTIS device is currently being tested in a first-in-human study at two leading medical centers in Israel. The company is optimistic about the progress and aims to make the CAPTIS a best-in-class device.
Investment
growth-positive
The European Commission Horizon 2020 Program Backs Filterlex's Embolic Protection Device - CAPTIS
Filterlex Medical has been selected for the Phase 2 Horizon 2020 SME Instrument program and will receive a two-year grant valued at €2.1m. The grant will support the execution of clinical trials for Filterlexs CAPTIS device, a full-body embolic protection device used during catheter-based structural heart procedures. The company has also recently raised $3M in financing. Filterlex aims to reduce the risk of stroke and other complications during these procedures. The grant and financing round are seen as a vote of confidence in the company and its device by the European Commission and industry partners.
Investment
Filterlex Medical, embolic protection device for reducing the risk of stroke - PetaCrunch
growth-positive
Filterlex Medical Raised $3M in Series A Financing
Filterlex Medical, a medical device start-up, has completed a series A round of financing, raising $3M. The company has developed an embolic protection device called CAPTIS, which reduces the risk of stroke and complications during catheter-based structural heart procedures. CAPTIS won the best innovation award at the PCR 2019 innovation competition and received a grant of $200,000 from the Jon DeHaan foundation. The device is securely positioned in the aorta and provides full-body embolic protection by deflecting, capturing, and removing embolic particles. Filterlex Medical plans to present the product to international cardiologists and believes it will become a must-have device for left-heart procedures such as TAVR.
Investment
